Apnimed (APMD) vs ArriVent BioPharma (AVBP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
ArriVent BioPharma is the larger company by market cap ($823.9 million vs $758.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APMD | AVBP |
|---|---|---|
| Share price | $18.22 | $16.71 |
| Market cap | $758.51M | $823.93M |
| 1-day change | +1.00% | -1.07% |
| YTD return | — | -16.95% |
| 1-year return | — | -19.74% |
| P/E ratio (TTM) | 2.52 | — |
| EPS (TTM) | $7.22 | $-3.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $35.29 | $35.83 |
| 52-week low | $16.12 | $11.36 |
| Distance from 52-week high | -48.37% | -53.36% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +176.23% | +82.53% |
| Average volume | 552.07K | 908.55K |
| Shares outstanding | 41.63M | 49.31M |
| Employees | 81 | 77 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Apnimed
APMD stock →Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets.
Health Care · Biotechnology: Pharmaceutical Preparations · 81 employees
About ArriVent BioPharma
AVBP stock →ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 77 employees
APMD vs AVBP FAQ
Which is bigger, Apnimed or ArriVent BioPharma?
ArriVent BioPharma (AVBP) is larger, with a market capitalization of $823.93M compared with $758.51M for Apnimed (APMD).
Are Apnimed and ArriVent BioPharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.